BL22 Immunotoxin in Treating Patients With Refractory Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, or Non-Hodgkin's Lymphoma

DISEASE CHARACTERISTICS: Diagnosis of B-cell leukemia or lymphoma of 1 of the following types: Chronic lymphocytic leukemia Failed standard chemotherapy Prolymphocytic leukemia Failed standard chemotherapy Indolent non-Hodgkin's lymphoma, including mantle cell lymphoma Stage III or IV disease Failed ≥ 1 prior doxorubicin- or fludarabine-containing standard therapy CD22-positive disease, as evidenced by 1 of the following: More than 15% malignant cells react with anti-CD22 by immunohistochemistry More than 30% malignant cells are CD22-positive by fluorescence-activated cell sorting analysis More than 400 CD22 sites per malignant cell (average) by radiolabeled anti-CD22 binding Treatment is medically indicated, as evidenced by any of the following: Progressive disease-related symptoms Progressive cytopenias due to marrow involvement Progressive or painful splenomegaly or adenopathy Rapidly increasing lymphocytosis Autoimmune hemolytic anemia or thrombocytopenia Increased frequency of infections No neutralizing anti-toxin or anti-mouse immunoglobulin G (IgG) antibodies to BL22 or PE38 No serum neutralization of > 75% of the activity of 1 μg/mL of BL22 No CNS disease requiring treatment No hairy cell leukemia PATIENT CHARACTERISTICS: Age 18 and over Performance status ECOG 0-2 Life expectancy More than 6 months Hematopoietic Absolute neutrophil count > 1,000/mm^3* Platelet count > 40,000/mm^3 NOTE: *Patients with leukemia are eligible regardless of absolute neutrophil count; Grade III-IV pancytopenia or growth factor dependence allowed if due to disease Hepatic Bilirubin < 1.5 times upper limit of normal (ULN) ALT and AST < 2.5 times ULN Renal Creatinine ≤ 1.5 mg/dL Pulmonary FEV1 ≥ 60% of predicted DLCO ≥ 55% of predicted Other Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception HIV negative PRIOR CONCURRENT THERAPY: Biologic therapy Prior bone marrow transplantation allowed More than 3 weeks since prior biologic therapy, including interferon, denileukin diftitox, or LMB-2 immunotoxin More than 3 months since prior monoclonal antibody therapy (e.g., rituximab) Chemotherapy See Disease Characteristics More than 3 weeks since prior cytotoxic chemotherapy Endocrine therapy More than 1 week since prior steriods Less than 5 doses for non-treatment reasons (e.g., allergy prophylaxis) No evidence of disease response Radiotherapy More than 3 weeks since prior whole-body electron beam radiotherapy Radiotherapy within the past 3 weeks allowed provided the volume of bone marrow treated is < 10% AND the patient has measurable disease located outside the radiation port Surgery Not specified Other More than 3 weeks since prior retinoids More than 3 weeks since other prior systemic therapy for this malignancy